The Sodium Iodide Symporter: Function in Health and Medicine

The sodium iodide symporter, commonly abbreviated NIS, is a membrane protein whose primary job is deceptively simple: it pulls iodide from the bloodstream into thyroid cells so the gland can manufacture thyroid hormones. That single function underpins one of the oldest and most effective targeted therapies in all of medicine, radioactive iodine treatment for thyroid cancer, and it turns out NIS does far more than serve the thyroid alone. Found in tissues from the lactating breast to the salivary glands to the placenta, NIS sits at an intersection of basic physiology, cancer biology, gene therapy, and environmental toxicology that makes it one of the most medically versatile proteins ever identified.

How NIS Moves Iodide Into Cells

Iodide is naturally present in the blood at very low concentrations, yet the thyroid gland concentrates it to levels 20 to 40 times higher than surrounding plasma. NIS accomplishes this against the concentration gradient by hitchhiking on sodium. The protein harnesses the natural flow of sodium ions into the cell, driven by the electrochemical gradient that all cells maintain, and uses that energy to drag iodide along for the ride. Electrophysiology experiments established that NIS moves two sodium ions for every one iodide ion, meaning each transport cycle carries a net positive charge into the cell.¹ This 2-to-1 stoichiometry is what makes the process “electrogenic,” giving it the thermodynamic push needed to concentrate iodide so dramatically inside thyroid follicular cells.

In 2022, researchers solved three-dimensional structures of rat NIS using cryo-electron microscopy, capturing the protein in three states: empty, loaded with two sodium ions and one iodide, and loaded with one sodium ion and the oxyanion perrhenate.² These snapshots revealed which amino acids grip the substrates and how the protein changes shape to shuttle them across the membrane. They also showed why NIS can transport certain other anions besides iodide, a quirk that has enormous consequences for both medicine and toxicology.

TSH and the Regulation of NIS

Thyroid-stimulating hormone, or TSH, is the master switch for iodide uptake. When TSH levels rise, the thyroid ramps up NIS production to capture more iodide and feed hormone synthesis. But the timeline is not instant. In cell studies, TSH begins increasing NIS gene activity within a few hours, yet the resulting protein does not reach peak levels for about 72 hours, and iodide transport activity follows a similar slow ramp.³ Interestingly, even in resting thyroid cells not stimulated by TSH, a substantial amount of NIS protein is already present in the membrane, about a third of the peak level, but it is barely active. That finding hinted early on that TSH does more than just make more NIS. It also flips existing NIS into an active state through additional signaling steps that researchers are still working out.

Studies in human thyroid cells confirmed a dose-dependent and time-dependent relationship, with NIS gene expression peaking around 24 hours after TSH stimulation.⁴ TSH works through at least two intracellular signaling routes. One pathway promotes NIS expression at high iodine concentrations while the other continues to suppress it, a push-and-pull arrangement that lets the thyroid fine-tune iodide uptake depending on how much iodine is already available.⁵ This built-in feedback helps prevent the gland from overdosing on iodide when dietary intake is high.

Why Getting NIS to the Cell Surface Matters

Making the NIS protein is only half the battle. The protein has to travel from the interior of the cell to the outer membrane to do its job, and that trafficking step depends heavily on a chemical modification called glycosylation, where sugar molecules are attached to the protein. When glycosylation is blocked experimentally, NIS stays stuck in the cell’s interior and very little iodide gets transported. When glycosylation proceeds normally, NIS moves to the membrane and iodide uptake increases.⁶ This detail matters in cancer, where tumor cells sometimes produce NIS protein but fail to deliver it to the surface, rendering the protein useless for iodide uptake even though it is technically present.

NIS Beyond the Thyroid

The thyroid gets most of the attention, but NIS is expressed across a surprisingly wide range of tissues. Gene-expression studies have detected NIS activity in the salivary glands, stomach lining, mammary gland, pituitary, pancreas, testis, prostate, ovary, and several other organs.⁷ The levels vary enormously. The thyroid, salivary glands, and stomach show the strongest expression, while other tissues express NIS at much lower levels whose physiological significance is still debated.

The mammary gland is a particularly well-studied case. NIS is switched on in breast tissue during lactation but not during non-lactating periods, allowing the nursing breast to actively concentrate iodide and deliver it to the infant through milk.⁸ This makes biological sense: a newborn’s thyroid needs iodide to begin synthesizing its own thyroid hormones, and breast milk is the sole dietary source in early life. Mouse studies confirmed that NIS gene expression is specifically upregulated in the mammary gland during lactation.⁹ The mammary gland appears to regulate how much NIS sits in its cell membranes by adjusting the protein’s glycosylation and degradation, fine-tuning milk iodine concentration in response to maternal iodine intake.¹⁰

The placenta also expresses NIS, and its levels change as pregnancy progresses. NIS gene activity in placental tissue is low at around six weeks of gestation, rises to a peak near 12 weeks, and continues climbing at the protein level as the placenta becomes more vascularized, meeting the growing fetus’s rising demand for iodide.¹¹ This timing aligns with the period when the fetal thyroid begins making its own hormones.

NIS in Thyroid Cancer

Radioactive iodine therapy has been a cornerstone of thyroid cancer treatment for decades, and it works precisely because NIS in thyroid cancer cells still transports iodide, including radioactive forms like iodine-131. The radioactive iodine accumulates inside the tumor cells and delivers a lethal dose of beta radiation from within. The therapeutic effect depends on the absorbed dose, with studies showing an initial delay before cell death kicks in, followed by both programmed cell death and, at higher doses, outright destruction of the cells.¹² Several radioisotopes can exploit NIS for imaging and treatment, including technetium-99m, iodine-123, iodine-131, iodine-124, and fluorine-18 tetrafluoroborate.¹³

The catch is that many thyroid cancers lose NIS expression as they become less differentiated. Papillary thyroid cancers, the most common type, show markedly reduced NIS gene expression compared with normal thyroid tissue, with studies reporting a median decrease of about 69% in cancerous tissue versus adjacent healthy tissue.¹⁴ This reduction is why many thyroid cancers appear as “cold” nodules on radioiodine scans, meaning they do not take up the tracer the way normal thyroid tissue does.¹⁵ Some research suggests this loss of NIS is an early event in the transformation from normal cell to cancer cell, rather than a consequence of tumor progression.¹⁶

The BRAF Mutation Problem

A specific genetic mutation called BRAF V600E is found in a large fraction of papillary thyroid cancers and has become a focus of intense clinical interest because of its relationship to NIS. Tumors carrying this mutation are more likely to show absent or very low NIS expression.¹⁷ A large meta-analysis confirmed that the BRAF V600E mutation is strongly associated with loss of iodine avidity, which is the clinical way of saying the tumor stops concentrating radioiodine, particularly in patients with recurrent disease.¹⁸ When a thyroid cancer no longer takes up radioiodine, it is classified as “radioiodine-refractory,” and the treatment options narrow considerably.

This has driven efforts to develop drugs that can reverse the process. The BRAF mutation activates a signaling cascade called the MAPK pathway, which suppresses NIS. Preclinical work has shown that inhibitors targeting this pathway can restore NIS expression, increase iodine uptake, and enhance radioiodine’s ability to kill tumor cells.¹⁹ These “redifferentiation” strategies aim to coax stubborn thyroid cancers back into behaving enough like normal thyroid tissue to become vulnerable to radioiodine again. Clinical trials testing this approach have shown encouraging preliminary results, though the field is still working out which patients benefit most and how durable the responses are.

Salivary Gland Damage From Radioiodine Therapy

Because NIS is highly expressed in the salivary glands, radioactive iodine concentrates there just as it does in the thyroid. This is the main reason patients receiving high-dose radioiodine therapy for thyroid cancer often experience salivary gland side effects. The radiation damages the delicate duct cells and stem cells of the glands, leading to painful swelling, dry mouth, altered taste, and in some cases chronic loss of salivary function that substantially affects quality of life.²⁰ The symptoms can appear immediately after treatment or develop months later and worsen over time.²¹

Several preventive strategies have been tried. Sour candy or lemon juice to stimulate saliva flow (sialogogues) is the most commonly recommended approach, with the idea that speeding up the passage of radioiodine through the glands reduces the radiation dose they absorb. Parotid gland massage has also shown promise, with one study finding it significantly reduced salivary gland dysfunction and markers of gland destruction at follow-up.²² There is no consensus on the best approach, and some proposed interventions like vitamin E and amifostine remain unproven, but the underlying biology is clear: NIS in the salivary glands is both the cause of the problem and the reason these preventive strategies focus on flushing the glands quickly.

Environmental Chemicals That Block NIS

NIS does not exclusively transport iodide. It will accept several other anions, and some of these act as competitive inhibitors, essentially clogging the transporter so iodide cannot get through. The most potent known inhibitor is perchlorate, a contaminant found in drinking water, certain fertilizers, and rocket propellant residue. On a molar basis, perchlorate is about 15 times more potent than thiocyanate (found in cigarette smoke and certain foods), 30 times more potent than iodide itself, and roughly 240 times more potent than nitrate (ubiquitous in vegetables and cured meats) at blocking iodide uptake.²³ These inhibitors act through simple competitive binding and their effects are additive, meaning a person exposed to moderate levels of all three simultaneously could face a meaningful reduction in iodide uptake even if each individual exposure seems low.

The concern is that by blocking NIS, these environmental chemicals can mimic or worsen the effects of iodine deficiency, potentially disrupting thyroid hormone production.²⁴ Populations already marginal in their iodine intake, such as pregnant women in regions without iodized salt programs, are thought to be most vulnerable, since even a modest further reduction in iodide transport could affect fetal brain development. This is also why perchlorate contamination in water supplies draws regulatory attention disproportionate to its acute toxicity: the risk is not poisoning in the traditional sense but subtle interference with a critical nutrient pathway.

NIS as a Tool for Gene Therapy and Imaging

The fact that NIS can concentrate radioactive tracers has made it attractive far beyond the thyroid. Researchers have adopted NIS as a “reporter gene,” a molecular tag that can be inserted into viruses, cells, or gene-therapy vectors so that their location in the body can be tracked using standard nuclear imaging techniques like SPECT and PET scans.²⁵ If a gene-therapy vector carrying NIS reaches the liver, for instance, that liver tissue will start concentrating radioactive tracers and light up on a scan. This lets clinicians monitor where a therapy has gone and how long it remains active without surgery or biopsy.²⁶

An even more ambitious application is using NIS gene transfer to make non-thyroid cancers vulnerable to radioiodine. The concept is straightforward: insert the NIS gene into tumor cells using a viral vector, let those cells start concentrating iodide, then treat the patient with iodine-131 just as you would for thyroid cancer. Researchers have demonstrated this in prostate cancer cells, using a prostate-specific gene promoter to drive NIS expression so that only prostate tissue accumulates the radioiodine. In both cell cultures and animal models, the approach produced enough iodide accumulation to achieve a therapeutic radiation dose.²⁷ The strategy has been explored for several other tumor types in preclinical settings. Translating this to actual patients remains challenging, primarily because getting the NIS gene into enough tumor cells and maintaining expression long enough to deliver meaningful radiation doses is harder in a living person than in a laboratory dish.

When NIS Itself Is Broken

Rare inherited mutations in the gene encoding NIS (known as SLC5A5) cause a condition called iodide transport defect, a form of congenital hypothyroidism. Affected individuals are born with a thyroid gland that simply cannot pull iodide from the blood, so it swells into a goiter while failing to make adequate thyroid hormones.²⁸ The condition is uncommon in humans but has also been documented in dogs, where a family of Shih Tzus was found to carry a homozygous splice-site mutation in SLC5A5 that caused the same syndrome of goiter and hypothyroidism.²⁹ These cases, while rare, confirm that NIS is truly indispensable for thyroid function and that no backup transporter can compensate when it fails.

NIS Across the Animal Kingdom

NIS is not a uniquely mammalian invention. The gene family it belongs to, the solute carrier family 5 (SLC5), is ancient and diversified across vertebrates. Evolutionary analyses have mapped out two major branches of these transporters: one containing NIS and related iodide and lactate cotransporters, and another containing the better-known sodium/glucose cotransporters. In stickleback fish, NIS-family genes are expressed in the thyroid, connective tissue, cartilage, teeth, and gonads during embryonic and larval development. Single-cell studies in zebrafish have detected NIS-family gene expression in germ cells of both sexes.³⁰ This widespread expression across species and tissues suggests that the protein’s role in concentrating iodide is an ancient function that was later co-opted by specialized organs like the mammalian thyroid and lactating mammary gland. It also means that environmental NIS inhibitors like perchlorate have the potential to disrupt iodide handling not just in humans but across aquatic and terrestrial wildlife, a consideration that increasingly shapes environmental risk assessments.

The use of NIS in medical imaging has even drawn on this evolutionary diversity. One research group engineered a version of NIS derived from the minke whale that is resistant to perchlorate inhibition, then incorporated it into a gene-therapy vector to improve the reliability of in-vivo tracking by avoiding interference from endogenous perchlorate-like substances.²⁶ It is a neat example of basic evolutionary biology feeding directly back into clinical innovation: studying how different species handle iodide has produced tools that work better in the lab and, potentially, in patients.